The Nussenzweig Lab will be conducting the first-in-human (FIH) clinical trials of monoclonal antibodies (mAb) against Hepatitis B and Tick Borne Encephalitis virus (TBEV) in the USA and Europe. The novel mAbs were isolated and cloned at Rockefeller University and are protective in animal models.
Nussenzweig’s laboratory studies the molecular aspects of the immune system’s innate and adaptive responses using a combination of biochemistry, molecular biology, and genetics. For work on adaptive immunity, he focuses on B lymphocytes and antibodies to HIV-1, while his studies of innate immunity focus on dendritic cells. His work is leading to new antibody-based therapies for infections by HIV and the novel SARS-CoV-2 coronavirus, among other viruses.
